Investigation of Efficacy and Safety of EPOGAM
NCT00878670
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
23
Enrollment
INDUSTRY
Sponsor class
Conditions
Atopic Dermatitis
Neurodermatitis
Interventions
DRUG:
EPOGAM 1000
Sponsor
Max Zeller Soehne AG